<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042324</url>
  </required_header>
  <id_info>
    <org_study_id>RMFPC-24</org_study_id>
    <nct_id>NCT04042324</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients</brief_title>
  <official_title>A Randomized 3 Period Crossover Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockwell Medical Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rockwell Medical Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effect of co-administration of Triferic and heparin on the&#xD;
      ability to maintain circuit anti-coagulation and iron delivery when compared to control&#xD;
      conditions when each treatment is administered via separate routes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Actual">January 16, 2020</completion_date>
  <primary_completion_date type="Actual">January 16, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-Xa Activity as Measured by the AUC (Area Under the Curve) 0-t</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-Xa Activity as Measured by the AUC (Area Under the Curve) 0-4 Hours</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aPTT (Activated Partial Thromboplastin Time) as Measured by the AUC (Area Under the Curve) 0-4 Hours</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TT (Thrombin Time) as Measured by the AUC (Area Under the Curve) 0-4 Hours</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron Profile as Measured by the sFe Cmax (Peak Serum Iron Concentration)</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron Profile as Measured by the AUC (Area Under the Curve) 0-t</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Triferic post-dialyzer; UFH via continuous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Triferic 6.75 mg IV over 3 hours into the post-dialyzer blood line (or drip chamber) administered by an infusion pump. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin using the on-machine infusion pump. The infusion of heparin to be stopped at hour 3 of hemodialysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UFH and Triferic admixture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Triferic 6.75 mg IV plus the appropriate volume of unfractionated heparin for continuous infusion over 3 hours into the pre-dialyzer &quot;heparin line&quot;. This mixture will be administered by the on-machine syringe infusion pump for continuous infusion. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of Triferic + heparin. The infusion of Triferic + heparin will be stopped at hour 3 of hemodialysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UFH via continuous infusion pre-dialyzer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive no Triferic. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin via the on-machine syringe pump. The infusion of heparin to be stopped at hour 3 of hemodialysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triferic</intervention_name>
    <description>Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.</description>
    <arm_group_label>Triferic post-dialyzer; UFH via continuous infusion</arm_group_label>
    <arm_group_label>UFH and Triferic admixture</arm_group_label>
    <other_name>ferric pyrophosphate citrate</other_name>
    <other_name>FPC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
    <arm_group_label>Triferic post-dialyzer; UFH via continuous infusion</arm_group_label>
    <arm_group_label>UFH and Triferic admixture</arm_group_label>
    <arm_group_label>UFH via continuous infusion pre-dialyzer</arm_group_label>
    <other_name>Unfractionated heparin</other_name>
    <other_name>UFH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult hemodialysis patients ≥18 years of age.&#xD;
&#xD;
          2. Signed informed consent to participate in the study.&#xD;
&#xD;
          3. Stable on hemodialysis prescription for ≥3 months.&#xD;
&#xD;
          4. Hemoglobin concentration &gt;9.5 g/dL.&#xD;
&#xD;
          5. Serum TSAT ≥20%.&#xD;
&#xD;
          6. Able to receive continuous heparin infusion as their anticoagulation protocol.&#xD;
&#xD;
          7. Receiving hemodialysis via AV (arteriovenous) fistula or graft.&#xD;
&#xD;
          8. Able to receive hemodialysis for 4 hours at each session over the duration of the&#xD;
             treatment periods.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active bleeding disorder (GI, skin, nasal…)&#xD;
&#xD;
          2. Receiving hemodialysis via catheter.&#xD;
&#xD;
          3. Receiving heparin free dialysis.&#xD;
&#xD;
          4. Receiving low molecular weight heparin as sole anti-coagulation for dialysis.&#xD;
&#xD;
          5. Receiving IV iron within 2 weeks of the first on-study hemodialysis treatment.&#xD;
&#xD;
          6. Receiving oral anti-coagulants or anti-platelet agents.&#xD;
&#xD;
          7. Any other condition, that in the opinion of the investigator would not allow&#xD;
             completion of the 3 hemodialysis treatments in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Pratt, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rockwell Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <results_first_submitted>June 19, 2020</results_first_submitted>
  <results_first_submitted_qc>October 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 12, 2020</results_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT04042324/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All twelve participants enrolled in the study were randomly assigned to cross-over between the three treatments on Days 1, 3 and 5.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>UFH and Triferic Admixture (Day 1)</title>
          <description>Patients will receive Triferic 6.75 mg IV plus the appropriate volume of unfractionated heparin for continuous infusion over 3 hours into the pre-dialyzer &quot;heparin line&quot;. This mixture will be administered by the on-machine syringe infusion pump for continuous infusion. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of Triferic + heparin. The infusion of Triferic + heparin will be stopped at hour 3 of hemodialysis.</description>
        </group>
        <group group_id="P2">
          <title>Triferic Post-dialyzer; UFH Via Continuous Infusion (Day 3)</title>
          <description>Patients will receive Triferic 6.75 mg IV over 3 hours into the post-dialyzer blood line (or drip chamber) administered by an infusion pump. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin using the on-machine infusion pump. The infusion of heparin to be stopped at hour 3 of hemodialysis.</description>
        </group>
        <group group_id="P3">
          <title>UFH Via Continuous Infusion Pre-dialyzer (Day 5)</title>
          <description>Patients will receive no Triferic. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin via the on-machine syringe pump. The infusion of heparin to be stopped at hour 3 of hemodialysis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>UFH and Triferic Admixture (Day 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Triferic Post-dialyzer (Day 3)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Triferic Pre-dialyzer (Day 5)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients enrolled in the study who received any amount of UFH, regardless of how the dose was administered.</population>
      <group_list>
        <group group_id="B1">
          <title>Safety Population</title>
          <description>All patients enrolled in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.0" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-Xa Activity as Measured by the AUC (Area Under the Curve) 0-t</title>
        <time_frame>8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>UFH and Triferic Admixture</title>
            <description>Patients will receive Triferic 6.75 mg IV plus the appropriate volume of unfractionated heparin for continuous infusion over 3 hours into the pre-dialyzer &quot;heparin line&quot;. This mixture will be administered by the on-machine syringe infusion pump for continuous infusion. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of Triferic + heparin. The infusion of Triferic + heparin will be stopped at hour 3 of hemodialysis.&#xD;
Triferic: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
          </group>
          <group group_id="O2">
            <title>UFH Via Continuous Infusion Pre-dialyzer</title>
            <description>Patients will receive no Triferic. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin via the on-machine syringe pump. The infusion of heparin to be stopped at hour 3 of hemodialysis&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Xa Activity as Measured by the AUC (Area Under the Curve) 0-t</title>
          <units>IU*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".798" spread="61.6"/>
                    <measurement group_id="O2" value=".733" spread="62.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-Xa Activity as Measured by the AUC (Area Under the Curve) 0-4 Hours</title>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triferic Post-dialyzer; UFH Via Continuous Infusion</title>
            <description>Patients will receive Triferic 6.75 mg IV over 3 hours into the post-dialyzer blood line (or drip chamber) administered by an infusion pump. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin using the on-machine infusion pump. The infusion of heparin to be stopped at hour 3 of hemodialysis.&#xD;
Triferic: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
          </group>
          <group group_id="O2">
            <title>UFH and Triferic Admixture</title>
            <description>Patients will receive Triferic 6.75 mg IV plus the appropriate volume of unfractionated heparin for continuous infusion over 3 hours into the pre-dialyzer &quot;heparin line&quot;. This mixture will be administered by the on-machine syringe infusion pump for continuous infusion. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of Triferic + heparin. The infusion of Triferic + heparin will be stopped at hour 3 of hemodialysis.&#xD;
Triferic: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
          </group>
          <group group_id="O3">
            <title>UFH Via Continuous Infusion Pre-dialyzer</title>
            <description>Patients will receive no Triferic. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin via the on-machine syringe pump. The infusion of heparin to be stopped at hour 3 of hemodialysis&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Xa Activity as Measured by the AUC (Area Under the Curve) 0-4 Hours</title>
          <units>IU*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".581" spread="75.7"/>
                    <measurement group_id="O2" value=".600" spread="77.9"/>
                    <measurement group_id="O3" value=".538" spread="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>aPTT (Activated Partial Thromboplastin Time) as Measured by the AUC (Area Under the Curve) 0-4 Hours</title>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triferic Post-dialyzer; UFH Via Continuous Infusion</title>
            <description>Patients will receive Triferic 6.75 mg IV over 3 hours into the post-dialyzer blood line (or drip chamber) administered by an infusion pump. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin using the on-machine infusion pump. The infusion of heparin to be stopped at hour 3 of hemodialysis.&#xD;
Triferic: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
          </group>
          <group group_id="O2">
            <title>UFH and Triferic Admixture</title>
            <description>Patients will receive Triferic 6.75 mg IV plus the appropriate volume of unfractionated heparin for continuous infusion over 3 hours into the pre-dialyzer &quot;heparin line&quot;. This mixture will be administered by the on-machine syringe infusion pump for continuous infusion. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of Triferic + heparin. The infusion of Triferic + heparin will be stopped at hour 3 of hemodialysis.&#xD;
Triferic: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
          </group>
          <group group_id="O3">
            <title>UFH Via Continuous Infusion Pre-dialyzer</title>
            <description>Patients will receive no Triferic. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin via the on-machine syringe pump. The infusion of heparin to be stopped at hour 3 of hemodialysis&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>aPTT (Activated Partial Thromboplastin Time) as Measured by the AUC (Area Under the Curve) 0-4 Hours</title>
          <units>IU*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188" spread="37.7"/>
                    <measurement group_id="O2" value="196" spread="38.5"/>
                    <measurement group_id="O3" value="188" spread="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TT (Thrombin Time) as Measured by the AUC (Area Under the Curve) 0-4 Hours</title>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triferic Post-dialyzer; UFH Via Continuous Infusion</title>
            <description>Patients will receive Triferic 6.75 mg IV over 3 hours into the post-dialyzer blood line (or drip chamber) administered by an infusion pump. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin using the on-machine infusion pump. The infusion of heparin to be stopped at hour 3 of hemodialysis.&#xD;
Triferic: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
          </group>
          <group group_id="O2">
            <title>UFH and Triferic Admixture</title>
            <description>Patients will receive Triferic 6.75 mg IV plus the appropriate volume of unfractionated heparin for continuous infusion over 3 hours into the pre-dialyzer &quot;heparin line&quot;. This mixture will be administered by the on-machine syringe infusion pump for continuous infusion. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of Triferic + heparin. The infusion of Triferic + heparin will be stopped at hour 3 of hemodialysis.&#xD;
Triferic: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
          </group>
          <group group_id="O3">
            <title>UFH Via Continuous Infusion Pre-dialyzer</title>
            <description>Patients will receive no Triferic. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin via the on-machine syringe pump. The infusion of heparin to be stopped at hour 3 of hemodialysis&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>TT (Thrombin Time) as Measured by the AUC (Area Under the Curve) 0-4 Hours</title>
          <units>IU*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" spread="31.6"/>
                    <measurement group_id="O2" value="98.0" spread="34.6"/>
                    <measurement group_id="O3" value="104" spread="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Iron Profile as Measured by the sFe Cmax (Peak Serum Iron Concentration)</title>
        <time_frame>8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triferic Post-dialyzer; UFH Via Continuous Infusion</title>
            <description>Patients will receive Triferic 6.75 mg IV over 3 hours into the post-dialyzer blood line (or drip chamber) administered by an infusion pump. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin using the on-machine infusion pump. The infusion of heparin to be stopped at hour 3 of hemodialysis.&#xD;
Triferic: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
          </group>
          <group group_id="O2">
            <title>UFH and Triferic Admixture</title>
            <description>Patients will receive Triferic 6.75 mg IV plus the appropriate volume of unfractionated heparin for continuous infusion over 3 hours into the pre-dialyzer &quot;heparin line&quot;. This mixture will be administered by the on-machine syringe infusion pump for continuous infusion. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of Triferic + heparin. The infusion of Triferic + heparin will be stopped at hour 3 of hemodialysis.&#xD;
Triferic: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Iron Profile as Measured by the sFe Cmax (Peak Serum Iron Concentration)</title>
          <units>ug/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180" spread="20.9"/>
                    <measurement group_id="O2" value="174" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Iron Profile as Measured by the AUC (Area Under the Curve) 0-t</title>
        <time_frame>8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triferic Post-dialyzer; UFH Via Continuous Infusion</title>
            <description>Patients will receive Triferic 6.75 mg IV over 3 hours into the post-dialyzer blood line (or drip chamber) administered by an infusion pump. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin using the on-machine infusion pump. The infusion of heparin to be stopped at hour 3 of hemodialysis.&#xD;
Triferic: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
          </group>
          <group group_id="O2">
            <title>UFH and Triferic Admixture</title>
            <description>Patients will receive Triferic 6.75 mg IV plus the appropriate volume of unfractionated heparin for continuous infusion over 3 hours into the pre-dialyzer &quot;heparin line&quot;. This mixture will be administered by the on-machine syringe infusion pump for continuous infusion. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of Triferic + heparin. The infusion of Triferic + heparin will be stopped at hour 3 of hemodialysis.&#xD;
Triferic: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Iron Profile as Measured by the AUC (Area Under the Curve) 0-t</title>
          <units>h*ug/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1040" spread="31.1"/>
                    <measurement group_id="O2" value="1050" spread="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1.5 weeks</time_frame>
      <desc>Adverse events were collected from date of enrollment through the date of final study visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Triferic Post-dialyzer; UFH Via Continuous Infusion</title>
          <description>Patients will receive Triferic 6.75 mg IV over 3 hours into the post-dialyzer blood line (or drip chamber) administered by an infusion pump. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin using the on-machine infusion pump. The infusion of heparin to be stopped at hour 3 of hemodialysis.&#xD;
Triferic: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
        </group>
        <group group_id="E2">
          <title>UFH and Triferic Admixture</title>
          <description>Patients will receive Triferic 6.75 mg IV plus the appropriate volume of unfractionated heparin for continuous infusion over 3 hours into the pre-dialyzer &quot;heparin line&quot;. This mixture will be administered by the on-machine syringe infusion pump for continuous infusion. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of Triferic + heparin. The infusion of Triferic + heparin will be stopped at hour 3 of hemodialysis.&#xD;
Triferic: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
        </group>
        <group group_id="E3">
          <title>UFH Via Continuous Infusion Pre-dialyzer</title>
          <description>Patients will receive no Triferic. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin via the on-machine syringe pump. The infusion of heparin to be stopped at hour 3 of hemodialysis&#xD;
Heparin: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Raymond Pratt, MD</name_or_title>
      <organization>Rockwell Medical, Inc</organization>
      <phone>248 960 9009 ext 405</phone>
      <email>rpratt@rockwellmed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

